Immupharma Share Discussion Threads

[coldspring] 18/2/2019 17:37

Lol @ badger

[badger60] 18/2/2019 12:08

Oh dear....

[gabberdemon] 11/2/2019 11:30

Lol. I don't feel let down one bit. In fact.. I still cannot wait for their success. Sometimes you have to appreciate that the best things achieved, often have lots a tumbles on the way up. The tumbles result in a much more established and successful outcome. I mean.. how many times did we fall as children, learning to stand and walk, then achieving our goal. It just takes time, tumbles, and patience :-)

[borromini1] 07/2/2019 10:32

Nobby - Not sure what you can provide by way of answers ... The letter you have seen, was that sent to existing Incanthera investors and not issued to the market? Is Tim stating that they can’t fund the costs of running an IPO? And what have Incanthera done with the £2m given them by Immupharma, is that capital ring fenced in some way?

[nobbygnome] 05/2/2019 20:41

I see Incanthera have failed to raise money for their IPO. I wonder how that will affect the deal with IMM? The letter from lyin Tim explaining the failure was full of the normal bullsh*t and obfuscation, which is absolutely typical of the man....

[badger60] 05/2/2019 09:30

NY BoyI dunno what's happening with SDX...but the oily that interests me is PMO where I did well last year. Good luck with your SDX ...and Hemogenyx of course........

[ny boy] 01/2/2019 13:06

Badger, I am in HEMO at much lower levels, holding 5-10 yrs

Still I am much more into (STX) as my banker bet for 2019 still only 50p to buy and if FDA approval comes through end of July (no reason why not, as already has EDA approval) and they tie up with a partner looking at 150p + imo but dyor, there are some good broker write ups on it on the thread.

Meanwhile, I also hold some of these, patience required

[kop202] 30/1/2019 09:17

How does it go....Down..Down deeper and down.....Name that tune!

[badger60] 29/1/2019 02:45

For those of you who must feel extremely let down and lost loads of money being sucked in buying IMM, here's your opportunity to make it back....and a lot more.....

How can I do that ! ? I hear you cry....


HEMOGENYX (HEMO) is the answer.........check it out for yourself.........

[michbens] 28/1/2019 18:08

So what happened to the buying volume??

[ny boy] 25/1/2019 18:06

No, looks more interesting, decent volume buying today, not a pump imo

[kirk 6] 25/1/2019 15:53

Great roll on 22p then

[michbens] 25/1/2019 15:30

Pump squad back on twitter.. look to me like a repeat of what happened before Christmas.. mini rise on absolutely nothing.

[kirk 6] 25/1/2019 15:25

Looks like this could fly shorty buying back in here Always looks good after ken chung

[ny boy] 25/1/2019 14:24

Bought a few of of theseir forthcoming news flows, reckon a x2 here by summer, meanwhile added STX, INFA & IDP GL

[ny boy] 24/1/2019 10:30

Lol!


(STX) is the one to be bullish about!

[ken chung] 24/1/2019 10:22

One of the best shorts around.

[bioking] 10/1/2019 15:03

OT) Please look at Futura Medical (FUM) has the BEST ERECTILE DYSFUNCTION DRUG out there wayy better than Viagra which is close to Phase 3 readout .Market cap is only 22 million Drug potential is 1+ BILLION =20++ BAGGER GEM ..


Research Confirms MED2002's US$1 Billion Potential
hxxps://futuramedical.com/content/news/archive17/060317b.asp

The latest market research further endorses Futura's strategy of developing MED2002 as a prescription product in standard and increased strength dose forms, with the objective of switching the standard dose form to an OTC product at an appropriate time.

Ipsos's validated healthcare forecasting model was used to predict peak OTC annual sales for MED2002 in key countries worldwide in excess of US$650 million. This forecast follows earlier market research commissioned into the potential of MED2002 as a prescription product, which indicated a prescription market size of up to US$600 million in key countries worldwide.

Ipsos forecasts that 70% of OTC product sales will be incremental to the prescription ED category. As a result, the estimated peak annual sales of MED2002 in prescription and OTC versions is predicted to be more than US$1 billion prior to the expiry of the product's expected patent life.

The Ipsos valuation was based on the outcomes from primary market research carried out amongst 400 men with ED or suspected ED in the USA. The respondents were in four groups: satisfied users of PDE5 inhibitors (the class of drugs such as Viagra and Cialis); dissatisfied users of PDE5 inhibitors; diagnosed but untreated ED sufferers; and suspected though undiagnosed ED sufferers. The respondents were shown a concept about MED2002 as part of the market research though they did not use the product as it is currently in clinical development.

The key findings of the market research showed that the respondents believed that the product, once approved, is highly differentiated from existing products and that its claims would meet their needs. MED2002's rapid onset of action, an average of less than five minutes, was the key feature that attracted respondents to the product and could command a price premium compared with existing ED treatments, which have a substantially slower onset of action.

The Ipsos healthcare forecasting model has been demonstrated by Ipsos to be within 20% of actual sales volumes in 9 out of 10 of its forecasts.


Pipeline
hxxps://www.futuramedical.com/media/144144/Pipeline-2018.jpg

MED2002 (topical treatment for erectile dysfunction) hxxps://futuramedical.com/content/products/med_2002.asp

first patient dosed: in Q3/Q4 2018
Last patient dosed: by end of June 2019
Headline efficacy results: by end of December 2019

CSD500: Erectogenic condom
hxxps://futuramedical.com/content/products/csd_500.asp

Significant milestone achieved with approval of 2-year shelf life approved for CSD500, the erectogenic condom in September 2018. Development now complete. Discussions are ongoing with current and potential further distribution partners on next steps with the product in a number of markets.

Pain relief products: TPR100 (diclofenac) and TIB200 (ibuprofen) hxxps://futuramedical.com/content/products/tpr_100.asp

TPR100 commercial partner Thornton & Ross filed for UK regulatory submission in July 2018.
Out-licensing discussions for TPR100 outside of the UK are ongoing.

[coldspring] 08/1/2019 21:31

He is trying to save all IMM shareholders as well as lupus sufferers worldwide. He should be seen as some sort of knight, all in his own mind of course.

[andyr42] 08/1/2019 21:24

Nobhead I think I haven't been here for about 4 months. Your posts today are exactly the same when I left. You have been denouncing IMM and its management for a long time now. You are not holding any shares so why, why, why??? You really do need help as something is seriously missing in your life. What a complete idiot you are.

[nobbygnome] 08/1/2019 21:10

>> youngharry

Somewhat ironically, our friend andy definitely needs to seek some therapy for anger management problems....